Clearside Biomedical, Inc. - Common Stock (CLSD)
0.3489
+0.0089 (2.62%)
NASDAQ · Last Trade: Jul 22nd, 9:45 AM EDT
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
Via Chartmill · July 21, 2025
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · July 21, 2025
Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · July 21, 2025
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · July 18, 2025
This week's M&A news includes strategic pivots and stumbles galore, with updates from WK Kellogg, Matador Restaurant and Windsurf.
Via Benzinga · July 18, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · July 18, 2025
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · July 18, 2025
Via Benzinga · July 18, 2025
Via Benzinga · July 18, 2025
Via Benzinga · July 17, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via Chartmill · July 17, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · July 17, 2025

Via Benzinga · June 3, 2025
Via Benzinga · April 23, 2025
Via Benzinga · April 17, 2025

Clearside Biomedical's CLS-AX Phase 2b trial for wet AMD met primary and secondary endpoints, showing stable vision and reduced injection frequency by 84% over 24 weeks, with no serious adverse events reported.
Via Benzinga · October 9, 2024

Via Benzinga · October 9, 2024